← Back to Search

Tegaderm vs. Transpore Eye Tape for Eyelid Redness

Waitlist Available
Research Sponsored by Tufts Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Surgeries scheduled for anesthesia of any duration
At least 18 years old
Must not have
Surgery in the prone position
Any surgery on the head, brain, neck, teeth, mouth, eyes, or face
Screening 3 weeks
Treatment Varies
Follow Up immediately after tape removal
Awards & highlights


This trial will compare the rate of erythema, or redness, on the eyelids after anesthesia when a TegadermTM patch is used compared to a Transpore® patch. The hypothesis is that there will be no difference in the rate of erythema between the two groups.

Who is the study for?
This trial is for adults over 18 who are scheduled for any surgery requiring anesthesia, except surgeries involving the head, neck, face, eyes or mouth. It's not for those with pre-existing eyelid redness or trauma, eyelid piercings, or anyone undergoing surgery in a prone position.Check my eligibility
What is being tested?
The study aims to compare Tegaderm Eye Tape and Transpore Eye Tape to see if there's a difference in causing eyelid redness after anesthesia. Participants will be randomly assigned one of the two tapes during their procedure.See study design
What are the potential side effects?
Potential side effects may include irritation at the tape application site leading to redness of the eyelids (eyelid erythema) following removal post-anesthesia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am scheduled for surgery that requires anesthesia.
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I will have surgery lying on my stomach.
I have had surgery on my head, brain, neck, teeth, mouth, eyes, or face.
I have redness or injury on my eyelid.
I am under 18 years old.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after tape removal
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after tape removal for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The proportion of eyelids with erythema at the end of surgery after removal of Tegaderm vs. Transpore
Secondary outcome measures
Epidermal Change

Trial Design

2Treatment groups
Experimental Treatment
Group I: Transpore RightExperimental Treatment1 Intervention
After general anesthesia is administered, Transpore will be placed on the right eye and Tegaderm will be placed on the left eye.
Group II: Tegaderm LeftExperimental Treatment1 Intervention
After general anesthesia is administered, Tegaderm will be placed on the left eye and Transpore will be placed on the right eye
First Studied
Drug Approval Stage
How many patients have taken this drug
Tegaderm Eye Tape
Transpore Eye Tape

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for eyelid redness include topical antibiotics, anti-inflammatory agents, and protective barriers like TegadermTM and Transpore®. Topical antibiotics, such as erythromycin, work by reducing bacterial load and preventing infection. Anti-inflammatory agents, like corticosteroids, decrease inflammation and redness by suppressing the immune response. Protective barriers, such as TegadermTM and Transpore®, shield the skin from external irritants and help maintain a moist environment, promoting healing. These treatments are crucial for patients with eyelid redness as they address the underlying causes of redness, reduce symptoms, and prevent complications.
Comparative Study on the Outcome of Periorbital Wrinkles Treated with Laser-Assisted Delivery of Vitamin C or Vitamin C Plus Growth Factors: A Randomized, Double-blind, Clinical Trial.Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction.Evaluating the quality of rosacea studies: implications for the patient and physician.

Find a Location

Who is running the clinical trial?

Tufts Medical CenterLead Sponsor
259 Previous Clinical Trials
264,048 Total Patients Enrolled

Media Library

Eye Protection Clinical Trial Eligibility Overview. Trial Name: NCT04918290 — N/A
Eyelid Redness Research Study Groups: Tegaderm Left, Transpore Right
Eyelid Redness Clinical Trial 2023: Eye Protection Highlights & Side Effects. Trial Name: NCT04918290 — N/A
Eye Protection 2023 Treatment Timeline for Medical Study. Trial Name: NCT04918290 — N/A
~40 spots leftby Jul 2025